Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Capricor Therapeutics Inc

Start price
Target price
Perf. (%)
€5.82
19.05.24
€10.00
-
20.05.24

MacroGenics Inc.

Start price
Target price
Perf. (%)
€3.91
19.05.24
€2.00
-
20.05.24

Protara Therapeutics Inc.

Start price
Target price
Perf. (%)
€2.90
19.05.24
€1.00
19.05.25
-5.52%
20.05.24

buy
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€12,000,000,000
-
19.05.24

Valuable balance sheet
Could be worthwhile Investment >10% per year
buy
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€12,000,000,000
-
19.05.24

Valuable balance sheet
Could be worthwhile Investment >10% per year
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€60,000,000
-
19.05.24

Valuable balance sheet
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€60,000,000
-
19.05.24

Valuable balance sheet
buy
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€60,000
-
19.05.24

Valuable balance sheet
buy
Discovery Communications C

Start price
Target price
Perf. (%)
€22.42
19.05.24
€60,000
-
19.05.24

Valuable balance sheet
buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€2.71
14.05.24
€3.00
14.05.25
25.85%
15.05.24

Good rating
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Insmed Inc.

Start price
Target price
Perf. (%)
€23.60
13.05.24
€15.00
13.05.25
0.00%
14.05.24

Could be very worthwhile Investment >20% year
MacroGenics Inc.

Start price
Target price
Perf. (%)
€3.91
13.05.24
€20.00
16.03.25
-
13.05.24

buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€2.36
13.05.24
€2.00
13.05.25
14.74%
14.05.24

Good rating
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Cytomx Therapeutics Inc

Start price
Target price
Perf. (%)
€1.83
11.05.24
€1.00
11.05.25
-3.66%
19.05.24

Revance Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.12
11.05.24
€1.00
11.05.25
-8.33%
19.05.24

MacroGenics Inc.

Start price
Target price
Perf. (%)
€3.14
11.05.24
€1.02
11.05.25
30.98%
19.05.24

buy
Biolife Solutions Inc

Start price
Target price
Perf. (%)
€18.50
11.05.24
€32.00
11.05.25
8.11%
19.05.24

buy
Novavax Inc.

Start price
Target price
Perf. (%)
€8.70
11.05.24
€82.00
11.05.25
39.26%
19.05.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
Low dividend yield expected
Novavax Inc.

Start price
Target price
Perf. (%)
€9.37
10.05.24
-
10.05.25
-7.12%
12.05.24

buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€4.37
10.05.24
-
10.05.25
-27.99%
12.05.24

Risky Investment
buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€5.17
10.05.24
-
10.05.25
-19.69%
14.05.24

buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.96
10.05.24
-
10.05.25
4.80%
11.05.24

Could be worthwhile Investment >10% per year
buy
Mersana Therapeutics

Start price
Target price
Perf. (%)
€2.41
10.05.24
-
10.05.25
0.62%
11.05.24

buy
Cytomx Therapeutics Inc

Start price
Target price
Perf. (%)
€2.60
09.05.24
-
09.05.25
-29.60%
13.05.24

Cytomx Therapeutics Inc

Start price
Target price
Perf. (%)
€3.85
08.05.24
-
08.05.25
-44.13%
09.05.24